Tamta Makharadze

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 772 citations

Radiology, Medicine, Bronchial Neoplasm +9

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng et al. · The Lancet Oncology · 2022 · 494 citations · Full text

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Nature Medicine · 2022 · 268 citations · Full text

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze et al. · Journal of Thoracic Oncology · 2023 · 85 citations · Full text

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 65 citations · Full text

Final Results, Oncology, Hepatology +10